Document is current
Any future updates will be listed below
-
Authors
Donovan, Micah G.
Eduthan, Neetha P.
Smith, Keith P.
Britton, Eleanor C.
Lyford, Hannah R. http://orcid.org/0000-0002-5165-9927
Araya, Paula
Granrath, Ross E.
Waugh, Katherine A.
Enriquez Estrada, Belinda
Rachubinski, Angela L. http://orcid.org/0000-0003-1150-3976
Sullivan, Kelly D. http://orcid.org/0000-0003-2725-0205
Galbraith, Matthew D. http://orcid.org/0000-0003-0485-3927
Espinosa, Joaquin M. http://orcid.org/0000-0001-9048-1941
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UM1TR004399)
Global Down Syndrome Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI150305)
- License Information
-
More Information
Article History
Received: 16 November 2023
Accepted: 18 June 2024
First Online: 28 June 2024
Competing interests
: J.M.E. has provided consulting services to Eli Lilly and Co., Gilead Sciences Inc., Biohaven Pharmaceuticals, and Perha Pharmaceuticals. All other authors declare that they have no competing interests.
